 Chiasma, Inc. CHMA, a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that William Ludlam, M.D., Ph.D., Senior Vice President of Clinical Development and Medical Affairs, will present at the 13th Acromegaly Consensus Conference, to be held from November 17th-19th in Fort Lauderdale, Florida. Dr. Ludlam is scheduled to present on Sunday, November 17th. We are pleased to be sharing positive top-line data from our Phase 3 CHIASMA OPTIMAL trial of MYCAPSSA, that is being developed for the maintenance treatment of adult acromegaly patients, at the conference this year, said Dr. William Ludlam. 